Insmed Reports First Quarter Financial Results

Insmed Reports First Quarter Financial Results 
Conference Call Begins at 8:30 a.m. Eastern Time Today 
MONMOUTH JUNCTION, NJ -- (Marketwired) -- 05/07/13 --  Insmed
Incorporated (NASDAQ: INSM), ("Insmed" or the "Company"), a
biopharmaceutical company focused on developing and commercializing
an inhaled anti-infective to treat patients battling serious lung
diseases that are often life-threatening, reported financial results
for the three months ended March 31, 2013. 
Highlights of the first quarter of 2013 and recent weeks included: 


 
--  Phase 3 update. Completed the patient treatment period of the
    Company's registrational Phase 3 clinical trial of ARIKACE(R), the
    Company's Iiposomal amikacin for inhalation, to treat cystic fibrosis
    (CF) patients with Pseudomonas lung infections in Europe and Canada
    and remain on track to report top-line clinical results from the trial
    in mid-2013.
--  Orphan Drug Designation. Received orphan drug designation from the
    U.S. Food and Drug Administration (FDA) Office of Orphan Products
    Development for the treatment of infections caused by non-tuberculous
    mycobacteria (NTM) for ARIKACE.
--  Cash Payment expected from Premacure. Reported that Premacure AB,
    recently acquired by Shire plc, elected to obtain all of the Company's
    rights to receive revenues for former product candidate, IGF-1, under
    the May 2012 Premacure License Agreement. Insmed expects to receive
    $11.5 million in May 2013 in exchange for any future royalties from
    Premacure, and Premacure will assume Insmed's royalty obligations to
    other parties.
--  Appointed Matt Pauls as Chief Commercial Officer. Mr. Pauls has more
    than 20 years of experience in the pharmaceutical industry, including
    senior-level leadership roles in global marketing, sales,
    reimbursement, new product launches and commercial operations at
    leading pharmaceutical companies.
--  Appointed Peter Clarke as Vice President of Manufacturing. Mr. Clarke
    has nearly 30 years of experience in biopharmaceutical manufacturing
    at both startup and established pharmaceutical companies in Europe and
    the United States.

  
"We continue to advance Insmed's transformation into a commercial
entity. During the first quarter we made significant
 progress in
executing our hiring plan, advancing our manufacturing strategy and
carrying out our clinical trials and regulatory filing preparation
for ARIKACE," stated Will Lewis, President and Chief Executive
Officer of Insmed.  
"We remain on track to report top-line clinical results from our
Phase 3 trial in CF mid-year and our Phase 2 trial in NTM before the
end of the year. Collectively, these data sets bring us closer to our
goal to commercialize a potentially life-saving treatment for
patients suffering from these orphan lung diseases." 
First Quarter Financial Results 
For the first quarter of 2013, Insmed posted a net loss of $13.7
million, or $0.43 per share, compared with a net loss of $6.8
million, or $0.28 per share, for the first quarter of 2012.  
Research and development expense in the first quarter increased to
$10.3 million from $4.7 million in the first quarter of 2012,
primarily due to a $4.6 million increase in external costs for
clinical trial activities associated with the Company's Phase 3 CF
clinical trial and two-year extension study in Europe and Canada, and
its Phase 2 NTM clinical trial in the United States. 
General and administrative expense for the first quarter of 2013
increased to $4.0 million from $2.5 million in the first quarter of
2012 primarily due to a $1.0 million increase in professional fees
related to the review, accounting and reporting of certain equity
awards previously granted to employees and directors that, at the
time of the grants, were in excess of annual per-person sub-limits
included in the Company's 2000 Stock Incentive Plan. The Company also
incurred an additional $0.3 million of non-cash stock compensation
expense resulting from re-measuring at fair value these equity
awards.  
During the first quarter the Company received $1.2 million in cash
from the sale of a portion of its New Jersey State net operating
losses (NOLs) under the State of New Jersey's Technology Business Tax
Certificate Transfer Program (the Program). The Program allows
qualified technology and biotechnology businesses in New Jersey to
sell unused amounts of NOLs and defined research and development tax
credits for cash. 
Balance Sheet Highlights and Cash Guidance 
As of March 31, 2013, Insmed had cash, cash equivalents and a
certificate of deposit totaling $81.6 million, compared with $92.9
million as of December 31, 2012. As of March 31, 2013, working
capital was $60.6 million, excluding a $2.2 million certificate of
deposit that matures in July 2013.  
As disclosed in the Company's Form 8-K filed on April 30, 2013, the
Company expects to receive $11.5 million in May 2013 from Premacure
as a result of Premacure's exercise of an option to obtain a fully
paid license to develop, manufacture and commercialize IGF-1, with
its natural binding protein, IGFBP-3, for the prevention and
treatment of complications of preterm birth.  
The Company estimates that its full year 2013 cash requirements to
fund operations will be in the range of $45 million to $55 million.
The Company expects current cash balances will be sufficient to fund
operations into 2014. 
Conference Call 
Insmed management will host an investment community conference call
to discuss these results and answer questions today beginning at 8:30
a.m. Eastern time. Shareholders and other interested parties may
participate in the call by dialing 888-803-5993 (domestic) or
706-634-5454 (international) and referencing conference ID number
56371335. The call will also be broadcast live on the Company's
website at www.insmed.com.  
A replay of the conference call will be accessible two hours after
its completion through May 21, 2013, by dialing 855-859-2056
(domestic) or 404-537-3406 (international) and referencing conference
ID number 56371335. The call will also be archived for 90 days on the
Company's website at www.insmed.com. 
About Insmed 
Insmed Incorporated is a biopharmaceutical company dedicated to
improving the lives of patients battling serious lung diseases.
Insmed is focused on the development and commercialization of
ARIKACE(R), or liposomal amikacin for inhalation, for at least two
identified orphan patient populations: cystic fibrosis (CF) patients
with Pseudomonas aeruginosa lung infections and patients with
non-tuberculous mycobacteria (NTM) lung infections. Insmed's Phase 3
registrational study of ARIKACE in CF patients in Europe and Canada
has completed and the Company expects top-line clinical results in
mid-2013. Insmed's Phase 2 clinical trial in patients with NTM is
under way in the United States and Canada, with clinical results
expected in late 2013. For more information, please visit
http://www.insmed.com. 
Forward-Looking Statements  
This release contains forward-looking statements that are made
pursuant to provisions of Section 21E of the Securities Exchange Act
of 1934. Words, and variations of words, such as "intend," "expect,"
"will," "anticipate," "believe," "continue," "propose" and similar
expressions are intended to identify forward-looking statements.
Investors are cautioned that such statements in this release,
including statements relating to the status, results and timing of
results of preclinical studies and clinical trials and preclinical
and cli
nical data and the anticipated benefits of Insmed's products,
and to the Company's cash position and financing needs, constitute
forward-looking statements that involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements. Such risks and uncertainties include,
without limitation, failure or delay of U.S. Food and Drug
Administration and other regulatory reviews and approvals,
competitive developments affecting the Company's product candidates,
delays in product development or clinical trials or other studies,
patent disputes and other intellectual property developments relating
to the Company's product candidates, unexpected regulatory actions,
delays or requests, the failure of clinical trials or other studies
or results of clinical trials or other studies that do not meet
expectations, inability to successfully develop the Company's product
candidates or receive necessary regulatory approvals, inability to
make product candidates commercially successful, changes in
anticipated expenses, changes in the Company's financing requirements
or ability raise additional capital, and other risks and challenges
detailed in the Company's filings with the U.S. Securities and
Exchange Commission, including its Annual Report on Form 10-K for the
year ended December 31, 2012. Investors are cautioned not to place
undue reliance on any forward-looking statements that speak only as
of the date of this news release. The Company undertakes no
obligation to update these forward-looking statements to reflect
events or circumstances or changes in its expectations. 
-Tables to Follow- 


 
                                                                            
                            INSMED INCORPORATED                             
                        Consolidated Balance Sheets                         
         (in thousands, except par value, share and per share data)         
                                                                            
                                                                            
                                                   March 31,   December 31, 
                                                     2013          2012     
                                                 ------------  ------------ 
                                                  (unaudited)               
Assets                                                                      
Current assets:                                                             
  Cash and cash equivalents                      $     79,434  $     90,782 
  Certificate of deposit                                2,173         2,153 
  Prepaid expenses and other current assets             1,418           643 
                                                 ------------  ------------ 
    Total current assets                               83,025        93,578 
                                                                            
In-process research and development                    58,200        58,200 
Other assets                                              110           117 
Fixed assets, net                                       1,681         1,666 
                                                 ------------  ------------ 
    Total assets                                 $    143,016  $    153,561 
                                                 ============  ============ 
                                                                            
Liabilities and shareholders' equity                                        
Current liabilities:                                                        
  Accounts payable                               $      8,184  $      7,060 
  Accrued expenses                                      5,329         2,933 
  Accrued compensation                                  1,359         2,207 
  Accrued lease expense, current                          298           295 
  Deferred rent                                           144           149 
  Capital lease obligations, current                       83            96 
  Current portion of long term debt                     4,875         3,007 
                                                 ------------  ------------ 
    Total current liabilities                          20,272        15,747 
                                                                            
Accrued lease expense, long-term                          580           647 
Capital lease obligations, long-term                       48            64 
Debt, long-term                                        14,511        16,221 
                                                 ------------  ------------ 
    Total liabilities                                  35,411        32,679 
                                                 ------------  ------------ 
                                                                            
                                                                            
Shareholders' equity:                                                       
Common stock, $0.01 par value; 500,000,000                                  
 authorized shares, 31,571,926 and 31,488,204                               
 issued and outstanding shares at March 31, 2013                            
 and December 31, 2012, respectively                      316           315 
  Additional paid-in capital                          455,725       455,325 
Warrant to purchase 329,932 shares of common                                
 stock for $2.94 per share at March 31, 2013 and                            
 December 31, 2012                                        790           790 
  Accumulated deficit                                (349,226)     (335,548)
                                                 ------------  ------------ 
Total shareholders' equity                            107,605       120,882 
                                                 ------------  ------------ 
    Total liabilities and shareholders' equity   $    143,016  $    153,561 
                                                 ============  ============ 
                                                                            
                                                                            
                            INSMED INCORPORATED                             
               Consolidated Statements of Comprehensive Loss                
                   (in thousands, except per share data)                    
                                                                            
                                                                            
                                                       Three Months Ended   
                                                            March 31,       
                                                        2013        2012    
                                                     ----------  ---------- 
                                                                            
Revenues                                             $        -  $        - 
                                                     ----------  ---------- 
                                                       
                     
Operating expenses:                                                         
  Research and development                               10,334       4,739 
  General and administrative                              3,975       2,525 
                                                     ----------  ---------- 
    Total operating expenses                             14,309       7,264 
                                                     ----------  ---------- 
                                                                            
Operating loss                                          (14,309)     (7,264)
                                                                            
Investment income                                            51         418 
Interest expense                                           (643)         (2)
Gain on sale of assets, net                                   2           5 
                                                     ----------  ---------- 
    Loss before income taxes                            (14,899)     (6,843)
                                                                            
Provision (benefit) for income taxes                     (1,221)          2 
                                                     ----------  ---------- 
                                                                            
Net loss                                             $  (13,678) $   (6,845)
                                                     ==========  ========== 
                                                                            
Basic and diluted net loss per share                 $    (0.43) $    (0.28)
                                                     ==========  ========== 
                                                                            
Weighted average basic and diluted common shares                            
 outstanding                                             31,554      24,860 
                                                     ==========  ========== 
                                                                            
                                                                            
Net loss                                             $  (13,678) $   (6,845)
Comprehensive loss:                                                         
  Unrealized gains on investments, net of taxes               -         216 
                                                     ----------  ---------- 
Comprehensive loss                                   $  (13,678) $   (6,629)
                                                     ==========  ========== 

  
Investor Relations Contacts:
LHA 
Anne Marie Fields 
Senior Vice President
212-838-3777
afields@lhai.com  
Bruce Voss
Managing Director
310-691-7100
bvoss@lhai.com 
 
 
Press spacebar to pause and continue. Press esc to stop.